Show simple item record

dc.creatorHughes, Darrel W.en
dc.creatorFrei, Christopher R.en
dc.creatorMaxwell, Pamela R.en
dc.creatorGreen, Kayen
dc.creatorPatterson, Jan E.en
dc.creatorCrawford, George E.en
dc.creatorLewis, James S.en
dc.date.accessioned2015-09-09T15:51:47Zen
dc.date.available2015-09-09T15:51:47Zen
dc.date.issued2009-05en
dc.identifier.citationHughes, D. W., Frei, C. R., Maxwell, P. R., Green, K., Patterson, J. E., Crawford, G. E., & Lewis, J. S. (May., 2009). Continuous versus Intermittent Infusion of Oxacillin for Treatment of Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 53(5), 2014–2019. doi:10.1128/AAC.01232-08en
dc.identifier.issn0066-4804en
dc.identifier.urihttp://hdl.handle.net/2152/31256en
dc.description.abstractInfective endocarditis (IE) is the fourth leading cause of life-threatening infection in the United States and imposes significant morbidity and mortality. The American Heart Association guidelines for the diagnosis and treatment of IE do not address continuous-infusion (CI) oxacillin. This retrospective study compares outcomes between CI oxacillin and intermittent-infusion (II) oxacillin in the treatment of IE caused by methicillin-susceptible Staphylococcus aureus (MSSA). A total of 709 medical records were reviewed for inpatients with definitive IE treated between 1 January 2000 and 31 December 2007. Continuous data were analyzed by Student's t test or the Wilcoxon rank sum test. The chi-square test or Fisher's exact test was used to compare nominal data. A multivariate logistic model was constructed. One hundred seven patients met eligibility criteria for inclusion into the study. Seventy-eight patients received CI oxacillin, whereas 28 received II oxacillin. CI and II groups were similar with respect to 30-day mortality (8% versus 10%, P = 0.7) and length of stay (20 versus 25 days, P = 0.4) but differed in 30-day microbiological cure (94% versus 79%, P = 0.03). Sixty-three patients received synergistic gentamicin, whereas 44 did not. The gentamicin and no-gentamicin groups were similar with respect to 30-day mortality (11% versus 4%, P = 0.2) and 30-day microbiological cure (90% versus 89%, P = 0.8); however, times to defervescence (4 versus 2 days, P = 0.02) were significantly different. CI oxacillin is an effective alternative to II oxacillin for the treatment of IE caused by MSSA and may improve microbiological cure. This convenient and pharmacodynamically optimized dosing regimen for oxacillin deserves consideration for patients with IE caused by MSSA.en
dc.description.sponsorshipen
dc.language.isoEnglishen
dc.rightsAdministrative deposit of works to Texas ScholarWorks: This works author(s) is or was a University faculty member, student or staff member; this article is already available through open access or the publisher allows a PDF version of the article to be freely posted online. The library makes the deposit as a matter of fair use (for scholarly, educational, and research purposes), and to preserve the work and further secure public access to the works of the University.en
dc.subjectantimicrobial therapyen
dc.subjectmedical progressen
dc.subjectdiagnosisen
dc.subjectcomplicationsen
dc.subjectmanagementen
dc.subjectcriteriaen
dc.subjectsurgeryen
dc.subjectmicrobiologyen
dc.subjectpharmacology & pharmacyen
dc.titleContinuous Versus Intermittent Infusion Of Oxacillin For Treatment Of Infective Endocarditis Caused By Methicillin-Susceptible Staphylococcus Aureusen
dc.typeArticleen
dc.rights.holderen
dc.description.departmentPharmacyen
dc.identifier.doi10.1128/aac.01232-08en
dc.identifier.urlen
dc.contributor.utaustinauthorHughes, Darrel W.en
dc.contributor.utaustinauthorFrei, Christopher R.en
dc.contributor.utaustinauthorMaxwell, Pamela R.en
dc.contributor.utaustinauthorLewis, James S.en
dc.relation.ispartofserialAntimicrobial Agents and Chemotherapyen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record